136 related articles for article (PubMed ID: 36514045)
21. Human autologous tumor-specific T cells in malignant melanoma.
Platsoucas CD
Cancer Metastasis Rev; 1991 Jun; 10(2):151-76. PubMed ID: 1873855
[TBL] [Abstract][Full Text] [Related]
22. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
Shah P; Forget MA; Frank ML; Jiang P; Sakellariou-Thompson D; Federico L; Khairullah R; Neutzler CA; Wistuba I; Chow CB; Long Y; Fujimoto J; Lin SY; Maitra A; Negrao MV; Mitchell KG; Weissferdt A; Vaporciyan AA; Cascone T; Roth JA; Zhang J; Sepesi B; Gibbons DL; Heymach JV; Haymaker CL; McGrail DJ; Reuben A; Bernatchez C
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110355
[TBL] [Abstract][Full Text] [Related]
23. TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.
Kongkaew T; Thaiwong R; Tudsamran S; Sae-Jung T; Sengprasert P; Vasuratna A; Suppipat K; Reantragoon R
J Immunol Methods; 2022 Apr; 503():113229. PubMed ID: 35101548
[TBL] [Abstract][Full Text] [Related]
24. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.
Dudley ME; Wunderlich JR; Shelton TE; Even J; Rosenberg SA
J Immunother; 2003; 26(4):332-42. PubMed ID: 12843795
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
26. Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.
Forget MA; Malu S; Liu H; Toth C; Maiti S; Kale C; Haymaker C; Bernatchez C; Huls H; Wang E; Marincola FM; Hwu P; Cooper LJ; Radvanyi LG
J Immunother; 2014; 37(9):448-60. PubMed ID: 25304728
[TBL] [Abstract][Full Text] [Related]
27. Adoptive CD8
Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
[TBL] [Abstract][Full Text] [Related]
28. The Outcome of
Poschke IC; Hassel JC; Rodriguez-Ehrenfried A; Lindner KAM; Heras-Murillo I; Appel LM; Lehmann J; Lövgren T; Wickström SL; Lauenstein C; Roth J; König AK; Haanen JBAG; van den Berg J; Kiessling R; Bergmann F; Flossdorf M; Strobel O; Offringa R
Clin Cancer Res; 2020 Aug; 26(16):4289-4301. PubMed ID: 32303540
[TBL] [Abstract][Full Text] [Related]
29. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.
Ben-Avi R; Farhi R; Ben-Nun A; Gorodner M; Greenberg E; Markel G; Schachter J; Itzhaki O; Besser MJ
Cancer Immunol Immunother; 2018 Aug; 67(8):1221-1230. PubMed ID: 29845338
[TBL] [Abstract][Full Text] [Related]
30. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
31. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Fix SM; Forget MA; Sakellariou-Thompson D; Wang Y; Griffiths TM; Lee M; Haymaker CL; Dominguez AL; Basar R; Reyes C; Kumar S; Meyer LA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35882447
[TBL] [Abstract][Full Text] [Related]
32. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
Gervois N; Heuze F; Diez E; Jotereau F
Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794
[TBL] [Abstract][Full Text] [Related]
33. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
Svane IM; Verdegaal EM
Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
[TBL] [Abstract][Full Text] [Related]
34. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.
Joseph RW; Peddareddigari VR; Liu P; Miller PW; Overwijk WW; Bekele NB; Ross MI; Lee JE; Gershenwald JE; Lucci A; Prieto VG; McMannis JD; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Hwu P; Radvanyi LG
Clin Cancer Res; 2011 Jul; 17(14):4882-91. PubMed ID: 21632855
[TBL] [Abstract][Full Text] [Related]
35. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
Johnson LA; Heemskerk B; Powell DJ; Cohen CJ; Morgan RA; Dudley ME; Robbins PF; Rosenberg SA
J Immunol; 2006 Nov; 177(9):6548-59. PubMed ID: 17056587
[TBL] [Abstract][Full Text] [Related]
36. Multi-omics study revealing the complexity and spatial heterogeneity of tumor-infiltrating lymphocytes in primary liver carcinoma.
Shi L; Zhang Y; Feng L; Wang L; Rong W; Wu F; Wu J; Zhang K; Cheng S
Oncotarget; 2017 May; 8(21):34844-34857. PubMed ID: 28422742
[TBL] [Abstract][Full Text] [Related]
37. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
[TBL] [Abstract][Full Text] [Related]
38. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
39. T cell receptor gene rearrangements and cytotoxic activities of clones isolated from tumour-infiltrating lymphocytes (TIL) from melanoma patients.
Pandolfi F; Boyle LA; Trentin L; Oliva A; Kurnick JT
Clin Exp Immunol; 1994 Jan; 95(1):141-7. PubMed ID: 8287599
[TBL] [Abstract][Full Text] [Related]
40. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.
Zhou J; Dudley ME; Rosenberg SA; Robbins PF
J Immunol; 2004 Dec; 173(12):7622-9. PubMed ID: 15585890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
